Adherence to capecitabine in preoperative treatment of stage II and III rectal cancer: do we need to worry?
Font R, Espinas JA, Layos L, Martinez Villacampa M, Capdevila J, Tobeña M, Pisa A, Pericay C, Lezcano C, Fort E, Cardona I, Berga N, Solà J, Borras JM
Ann Oncol
2017.
4.
831-835.
PMID: 28327898.
RD12/0036/0053
Understanding variations in the use of hypofractionated radiotherapy and its specific indications for breast cancer: A mixed-methods study.
Prades J, Algara M, Espinàs JA, Farrús B, Arenas M, Reyes V, García-Reglero V, Cambra MJ, Rubio E, Anglada L, Eraso A, Pedro A, Fuentes-Raspall MJ, Tuset V, Solà J, Borras JM
Radiother Oncol
2017.
1.
22-28.
PMID: 28236538.
RD12/0036/0053
Current developments in cancer care: including the patients' perspective-3rd European Roundtable Meeting (ERTM) June 17, 2016, Berlin, Germany.
Ortmann O, Rösler W, Helbig U, participants of the ERTM.
J Cancer Res Clin Oncol
2017.
4.
673-676.
PMID: 27988842.
RD12/0036/0005
Snail1-expressing fibroblasts as a source of paracrine signals in colon cancer tumors
Herrera A, Herrera M, Alba-Castellón L, Silva J, García V, Loubat J, Alvarez-Cienfuegos A, García JM, Rodríguez R, Gil B, Citores MJ, Larriba MJ, Casal JI, García de Herreros A, Bonilla F, Peña C
2014.
Grupos colaboradores: RD12/0036/0005 , RD12/0036/0041
RD12/0036/0005
The Epithelial-to-Mesenchymal Transition (EMT), a Particular Case.
Cebrià-Costa JP, Millanes-Romero A, de Herreros AG, Peiró S
Mol Cell Oncol
2014.
2.
e960770.
PMID: 27308335.
RD12/0036/0005
Snail1 controls cooperative cell plasticity during metastasis.
Herranz N, Dave N, Millanes-Romero A, Pascual-Reguant L, Morey L, Díaz VM, Lórenz-Fonfría V, Gutierrez-Gallego R, Jerónimo C, Iturbide A, Di Croce L, García de Herreros A, Peiró S
FEBS J
2016.
23.
4263-4273.
PMID: 27735137.
RD12/0036/0005
Pharmacological Approaches in an Experimental Model of Non-Small Cell Lung Cancer: Effects on Tumor Biology.
Donor CTLA-4 Genotype Modulates the Immune Response to Minor Histocompatibility Antigen Mismatches.
Gallardo D, Bosch-Vizcaya A, Rodríguez-Romanos R, Santos N, Buño I, de la Cámara R, Brunet S, Jiménez-Velasco A, González M, Nieto JB, Martínez-Laperche C, Vallejo C, Ferrá C, Sampol A, López-Jiménez J, Pérez-Simón JA, Martínez C, Díez JL, GvHD/Immunotherapy Committee of the Spanish Hematopoietic Transplant Group.
Grupos colaboradores: RD12/0036/0069 , RD12/0036/0052
RD12/0036/0014
A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome.
Huerta A, Arjona E, Portoles J, Lopez-Sanchez P, Rabasco C, Espinosa M, Cavero T, Blasco M, Cao M, Manrique J, Cabello-Chavez V, Suñer M, Heras M, Fulladosa X, Belmar L, Sempere A, Peralta C, Castillo L, Arnau A, Praga M, Rodriguez de Cordoba S
Kidney Int
2017.
PMID: 28911789.
RD12/0036/0014
Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT.
Baron F, Ruggeri A, Beohou E, Labopin M, Mohty M, Blaise D, Cornelissen JJ, Chevallier P, Sanz G, Petersen E, Savani BN, Gluckman E, Nagler A
J Hematol Oncol
2017.
1.
128.
PMID: 28637512.
RD12/0036/0014
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS
N Engl J Med
2017.
9.
836-847.
PMID: 28249141.
RD12/0036/0014
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Döhner H
N Engl J Med
2017.
5.
454-464.
PMID: 28644114.
RD12/0036/0014
Infectious Complications after Umbilical Cord-Blood Transplantation from Unrelated Donors.
Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML.
Kwon M, Bautista G, Balsalobre P, Sánchez-Ortega I, Montesinos P, Bermúdez A, de Laiglesia A, Herrera P, Martin C, Humala K, Zabalza A, Torres M, Bento L, Corral LL, Heras I, Serrano D, Buño I, Anguita J, Regidor C, Duarte R, Cabrera R, Gayoso J, Diez-Martin JL
Bone Marrow Transplant
2017.
8.
1138-1143.
PMID: 28346415.
RD12/0036/0014
Characterization of three new HLA Class I Alleles in Spanish Caucasians, HLA-A*02:620, HLA-B*27:150 and HLA-B*07:05:01:02.
Balas A, Planelles D, Montesinos P, Solano C, Vicario JL
Int J Immunogenet
2017.
3.
148-150.
PMID: 28383785.
RD12/0036/0014
Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy.
Martínez-Cuadrón D, Montesinos P, Vellenga E, Bernal T, Salamero O, Holowiecka A, Brunet S, Gil C, Benavente C, Ribera JM, Pérez-Encinas M, De la Serna J, Esteve J, Rubio V, González-Campos J, Escoda L, Amutio ME, Arnan M, Arias J, Negri S, Lowënberg B, Sanz MA
Leukemia
2017.
PMID: 28584252.
RD12/0036/0014
Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy.
Abla O, Ribeiro RC, Testi AM, Montesinos P, Creutzig U, Sung L, Di Giuseppe G, Stephens D, Feusner JH, Powell BL, Hasle H, Kaspers GJL, Dalla-Pozza L, Lassaletta A, Tallman MS, Locatelli F, Reinhardt D, Lo-Coco F, Hitzler J, Sanz MA
Ann Hematol
2017.
9.
1449-1456.
PMID: 28597167.
RD12/0036/0014
Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).
Validation of R-MIPI and prognostic value of immunoglobulin light chain restriction in mantle cell lymphoma.
Villegas Da Ros C, Linares Garcia M, Ortiz Zuluaga S, Javier Gonzalez K, Costa S, Roig M, Perez Rodriguez PL, Orero Castello M, Luna I, López-Pavía M, Sanchez M, Carbonell F
Br J Haematol
2017.
5.
816-818.
PMID: 27125335.
RD12/0036/0014
Impact of azacitidine on red blood cell alloimmunisation in myelodysplastic syndrome.
Ortiz S, Orero MT, Javier K, Villegas C, Luna I, Pérez P, Roig M, López M, Costa S, Carbonell F, Collado R, Ivars D, Linares M
Blood Transfus
2017.
5.
472-477.
PMID: 27416573.
RD12/0036/0014
Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure.
Jiménez-Ubieto A, Grande C, Caballero D, Yáñez L, Novelli S, Hernández-Garcia MT, Manzanares M, Arranz R, Ferreiro JJ, Bobillo S, Mercadal S, Galeo A, López Jiménez J, Moraleda JM, Vallejo C, Albo C, Pérez E, Marrero C, Magnano L, Palomera L, Jarque I, Martínez-Sánchez P, Martín A, Coria E, López-Guillermo A, Salar A, Lahuerta JJ
IgG subclasses quantitation: Analytical performance of The Binding Site SPAPLUS® human assay and comparison with Siemens BNII® assay.
Sarnago A, Pascual RM, Moreno MJ, Laíz B, Fuster O
Clin Biochem
2017.
PMID: 28912097.
RD12/0036/0014
Circulating MicroRNAs as Novel Biomarkers of Stenosis Progression in Asymptomatic Carotid Stenosis.
Dolz S, Górriz D, Tembl JI, Sánchez D, Fortea G, Parkhutik V, Lago A
Stroke
2017.
1.
10-16.
PMID: 27899750.
RD12/0036/0014
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.
Jakubowiak A, Offidani M, Pégourie B, De La Rubia J, Garderet L, Laribi K, Bosi A, Marasca R, Laubach J, Mohrbacher A, Carella AM, Singhal AK, Tsao LC, Lynch M, Bleickardt E, Jou YM, Robbins M, Palumbo A
Blood
2016.
23.
2833-40.
PMID: 27091875.
RD12/0036/0014
Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option.
Román E, Mendizábal S, Jarque I, de la Rubia J, Sempere A, Morales E, Praga M, Ávila A, Górriz JL
Nefrologia
2017.
5.
478-491.
PMID: 28946961.
RD12/0036/0014
Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.
Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.
Forero-Castro M, Robledo C, Benito R, Bodega-Mayor I, Rapado I, Hernández-Sánchez M, Abáigar M, Maria Hernández-Sánchez J, Quijada-Álamo M, María Sánchez-Pina J, Sala-Valdés M, Araujo-Silva F, Kohlmann A, Luis Fuster J, Arefi M, de Las Heras N, Riesco S, Rodríguez JN, Hermosín L, Ribera J, Camos Guijosa M, Ramírez M, de Heredia Rubio CD, Barragán E, Martínez J, Ribera JM, Fernández-Ruiz E, Hernández-Rivas JM
Br J Cancer
2017.
2.
256-265.
PMID: 28557976.
RD12/0036/0014
Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
Iaccarino L, Ottone T, Hasan SK, Divona M, Cicconi L, Lavorgna S, Alfonso V, Basso G, Barragán E, Bocchia M, Rego EM, Grimwade D, Voso MT, Lo-Coco F
Leuk Lymphoma
2017.
1-3.
PMID: 28838264.
RD12/0036/0034
Klf4 and Klf5 differentially inhibit mesoderm and endoderm differentiation in embryonic stem cells.
Aksoy I, Giudice V, Delahaye E, Wianny F, Aubry M, Mure M, Chen J, Jauch R, Bogu GK, Nolden T, Himmelbauer H, Xavier Doss M, Sachinidis A, Schulz H, Hummel O, Martinelli P, Hübner N, Stanton LW, Real FX, Bourillot PY, Savatier P
Nat Commun
2014.
3719.
PMID: 24770696.
RD12/0036/0034
Phacomatosis pigmentokeratotica is caused by a postzygotic HRAS mutation in a multipotent progenitor cell.
Groesser L, Herschberger E, Sagrera A, Shwayder T, Flux K, Ehmann L, Wollenberg A, Torrelo A, Bagazgoitia L, Diaz-Ley B, Tinschert S, Oschlies I, Singer S, Mickler M, Toll A, Landthaler M, Real FX, Hafner C
ICAT is a novel Ptf1a interactor that regulates pancreatic acinar differentiation and displays altered expression in tumours.
Campos ML, Sánchez-Arévalo Lobo VJ, Rodolosse A, Gottardi CJ, Mafficini A, Beghelli S, Scardoni M, Bassi C, Scarpa A, Real FX
Biochem J
2013.
3.
395-405.
PMID: 23339455.
RD12/0036/0034
Gata6 is required for complete acinar differentiation and maintenance of the exocrine pancreas in adult mice.
Martinelli P, Cañamero M, del Pozo N, Madriles F, Zapata A, Real FX
Gut
2013.
10.
1481-8.
PMID: 23002247.
RD12/0036/0013
Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP, and SEFH.
Garrido P, Aldaz A, Vera R, Calleja MA, de Álava E, Martín M, Matías-Guiu X, Palacios J
Clin Transl Oncol
2017.
PMID: 28861725.
Grupos colaboradores: RD12/0036/0017 , RD12/0036/0013
RD12/0036/0013
Metabolomic and Lipidomic Profiling Identifies The Role of the RNA Editing Pathway in Endometrial Carcinogenesis.
Altadill T, Dowdy TM, Gill K, Reques A, Menon SS, Moiola CP, Lopez-Gil C, Coll E, Matias-Guiu X, Cabrera S, Garcia A, Reventos J, Byers SW, Gil-Moreno A, Cheema AK, Colas E
Sci Rep
2017.
1.
8803.
PMID: 28821813.
RD12/0036/0013
Targeted proteomics identifies proteomic signatures in liquid-biopsies of the endometrium to diagnose endometrial cancer and assist in the prediction of the optimal surgical treatment.
Martinez E, Lesur A, Devis L, Cabrera S, Matias-Guiu X, Hirschfeld M, Asberger J, van Oostrum J, Casares de Cal MLÁ, Gómez-Tato A, Reventos J, Domon B, Colas E, Gil-Moreno A
Clin Cancer Res
2017.
PMID: 28790116.
RD12/0036/0013
TGF? Controls Ovarian Cancer Cell Proliferation.
Alsina-Sanchís E, Figueras A, Lahiguera A, Gil-Martín M, Pardo B, Piulats JM, Martí L, Ponce J, Matias-Guiu X, Vidal A, Villanueva A, Viñals F
Int J Mol Sci
2017.
8.
PMID: 28758950.
RD12/0036/0013
Tumor Heterogeneity in Endometrial Carcinoma: Practical Consequences.
Gatius S, Cuevas D, Fernández C, Roman-Canal B, Adamoli V, Piulats JM, Eritja N, Martin-Satue M, Moreno-Bueno G, Matias-Guiu X
Red Temática Investigación Cooperativa en Cáncer (RTICC)
Centro de Investigación Cáncer -
Campus Miguel de Unamuno -
37007 - Salamanca
(+34) 923294803 - sec.rticc[arroba]usal.es